310881-48-2

Basic information

• Product Name: 3-(PIPERIDIN-4-YLOXY)-PYRIDINE
• Synonyms: CHEMBRDG-BB 4004839;3-(PIPERIDIN-4-YLOXY)-PYRIDINE;3-(piperidin-4-yloxy)pyridine(SALTDATA: FREE)
• CAS NO: 310881-48-2
• Molecular Formula: C₁₀H₁₄N₂O
• Molecular Weight: 178.23
• Mol File: 310881-48-2.mol

Chemical Properties

• Boiling Point: 301.8°C at 760 mmHg
• Flash Point: 136.3°C
• Appearance: /
• Density: 1.078g/cm³
• Vapor Pressure: 0.00103mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.58±0.10(Predicted)
• CAS DataBase Reference: 3-(PIPERIDIN-4-YLOXY)-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(PIPERIDIN-4-YLOXY)-PYRIDINE(310881-48-2)
• EPA Substance Registry System: 3-(PIPERIDIN-4-YLOXY)-PYRIDINE(310881-48-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 310881-48-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(PIPERIDIN-4-YLOXY)-PYRIDINE is used as a key intermediate in the synthesis of various bicyclic derivatives, which are known for their inhibitory properties. These derivatives have potential applications in the development of new drugs and therapies for various medical conditions.
Used in Inhibitor Preparation:
3-(PIPERIDIN-4-YLOXY)-PYRIDINE is utilized in the preparation of inhibitors containing bicyclic derivatives. These inhibitors are designed to target specific biological processes or pathways, making them valuable tools in the development of targeted therapies for a range of diseases and disorders.
Used in Medical Applications:
The bicyclic derivatives synthesized using 3-(PIPERIDIN-4-YLOXY)-PYRIDINE have potential medical applications, as they can be developed into drugs that modulate specific biological targets. This can lead to the creation of novel treatments for various diseases, including cancer, neurological disorders, and inflammatory conditions.

InChI:InChI=1/C10H14N2O/c1-2-10(8-12-5-1)13-9-3-6-11-7-4-9/h1-2,5,8-9,11H,3-4,6-7H2

Upstream product

• 310881-47-1 1,1-dimethylethyl 4-(3'-pyridinyloxy)-1-piperidinecarboxylate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 1454648-71-5 (S)-3-{4-[4-(pyridin-3-yloxy)-piperidin-1-ylmethyl]-phenyl}-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine trifluoroacetate 

Relevant articles and documents

Pharmaceutical compositions and methods for use

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines. Exemplary compounds include dimethyl(2-(3-pyridyloxy)ethylamine, dimethyl(4-(3-pyridyloxy)butyl)amine, 2-(3-pyridyloxy)ethylamine, 4-(3-pyridyloxy)butylamine, methyl(3-(5-methoxy-3-pyridyloxy)propyl)amine, ethyl(3-(3-pyridyloxy)propyl)amine, methyl(2-(3-pyridyloxy)ethyl)amine, methyl(3-(6-methyl(3-pyridyloxy))propyl)amine, (3-(3-methoxyphenoxy)propyl)methylamine, (3-(5-chloro(3-pyridyloxy))-1-methylpropyl)methylamine, dimethyl(3-(3-pyridyloxy)propyl)amine, 3-(3-pyridyloxy)propylamine, methyl(4-(3-pyridyloxy)butyl)amine, 3-(5-chloro-3-pyridyloxy)propylamine, methyl(3-(5-isopropoxy-3-pyridyloxy)propyl)amine, (3-(5-chloro(3-pyridyloxy))propyl)methylamine, methyl(3-(5-(phenylmethoxy)(3-pyridyloxy))propyl)amine, methyl(3-(2-methyl(3-pyridyloxy))propyl)amine, (methylethyl)(3-(3-pyridyloxy)propyl)amine, benzyl(3-(3-pyridyloxy)propyl)amine, cyclopropyl(3-(3-pyridyloxy)-propyl)amine, methyl(1-methyl-3-(3-pyridyloxy)propyl)amine, methyl(3-(3-nitrophenoxy)propyl)amine, 1-(3-chloropropoxy)-3-nitrobenzene, (3-(3-aminophenoxy)propyl)methylamine, dimethyl(3-(3-(methylamino)-propoxy)phenyl)amine, methyl(3-tricyclo[7.3.1.0]tridec-2-yloxypropyl)amine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, 3-(4-piperidinyloxy)pyridine and 3-((3S)-3-pyrrolidinyloxy)pyridine.

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines and arylthioalkylamines, including pyridyloxylalkylamines, phenoxyalkylamines, pyridylthiolalkylamines and phenylthioalkylamines. Exemplary compounds include (2-(5-bromo(3-pyridylthio))ethyl)methylamine, (2-(5-bromo(3-pyridylthio))isopropyl)methylamine, (2-(5-bromo(3-pyridylthio))propyl)methylamine, (3-(5-bromo(3-pyridylthio))propyl)methylamine, 3-((3S)-3-pyrrolidinyloxy)pyridine, 3-(4-piperidinyloxy)pyridine, 3-(1-methyl-4-piperidinyloxy)pyridine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, and methyl(3-tricyclo[7.3.1.0]tridec-2-yloxypropyl)amine.

Synthesis and structure-activity relationship of novel pyridyl ethers for the nicotinic acetylcholine receptor

The preparation of novel pyridyl ethers as ligands for the nicotinic acetylcholine receptor (nAChR) is described. Variations of the ring size of the azacycle and substitution on the pyridine had dramatic effects on receptor binding affinity with IC50S at the α4β2 nAChR ranging from 22 to >10,000 nM. The most potent molecule was (R)-2-chloro-3-(4-cyanophenyl)-5-((3-pyrrolidinyl)oxy)pyridine 27f with an IC50 of 22 nM. (C) 2000 Elsevier Science Ltd. All rights reserved.